Back to Authors

Krishnamurthi, S

A5108589412 | I180857899

Mayo Clinic

Pfizer (United States)

Citations 1

A phase 1–2 clinical study of a second generation oral MEK inhibitor, PD 0325901 in patients with advanced cancer

Journal of Clinical Oncology | February 23, 2017 | Volume: 23 | Issue: 16_suppl | Pages: 3011-3011

10.1200/jco.2005.23.16_suppl.3011